Yin Yue, Hu Yusen, Li Yanning, Peng Xia, Liao Huanjin, Shen Wei, Li Li
Department of Laboratory Medicine, Shanghai General Hospital, Shanghai, People's Republic of China.
Department of Gastroenterology, Shanghai General Hospital, Shanghai, People's Republic of China.
J Asthma Allergy. 2024 Sep 11;17:833-845. doi: 10.2147/JAA.S476501. eCollection 2024.
Mast cells can be activated in various ways and were shown to be involved in the development of Crohn's disease (CD). The diagnosis of CD is still challenging, and seeking novel biomarkers is a worthwhile endeavor.
An indirect enzyme-linked immunosorbent assay (ELISA) was successfully established for semi-quantitative detection of IgG anti-FcεRI in serum using human FcεRIα coated microplates and an enzyme-labeled anti-human IgG as secondary antibodies. The optimal working conditions were explored, followed by conducting the method evaluation. The serum samples and clinical data of 117 CD patients and 75 healthy controls were collected. IgE was measured by the rate turbidity turbidimetry; IgG anti-IgE and IgG anti-FcεRI were detected by ELISA. IgG anti-pancreatic antibody (PAB) and anti-Saccharomyces cerevisiae antibody (ASCA) were determined by indirect immunofluorescence assay. Data were analyzed concerning the clinical characteristics.
IgG anti-FcεRI was an effective marker for CD ( < 0.001), but IgE and IgG anti-IgE ( = 0.089, 0.219, respectively) were not. There was a positive correlation between anti-IgE and anti-FcεRI (R = 0.380, < 0.001). Anti-FcεRI positive patients behaved with higher disease activity [OR: 1.478 (1.2001.821), < 0.001], but were less likely to be located in L4 among Montreal classification [OR: 0.253 (0.0770.837), = 0.024]. Existing indicators, PAB and ASCA, behaved with high specificity (both > 95%) with low sensitivity (both < 30%). The combination of anti-FcεRI with existing markers significantly improved the diagnostic efficiency [AUC: 0.879 (0.831~0.928)].
An ELISA for the detection of anti-FcεRI was established and validated, which may contribute to facilitating research on Crohn's diseases. Anti-FcεRI positive CD patients were associated with higher disease activity indices, suggesting its potential value in the diagnosis and management of CD.
肥大细胞可通过多种方式被激活，且已证明其参与克罗恩病（CD）的发病过程。CD的诊断仍具有挑战性，寻找新型生物标志物是一项有价值的工作。
使用人FcεRIα包被的微孔板和酶标记的抗人IgG作为二抗，成功建立了一种间接酶联免疫吸附测定（ELISA）法，用于半定量检测血清中的IgG抗FcεRI。探索了最佳工作条件，随后进行方法评估。收集了117例CD患者和75例健康对照者的血清样本及临床数据。采用速率散射比浊法测定IgE；采用ELISA法检测IgG抗IgE和IgG抗FcεRI。采用间接免疫荧光法测定IgG抗胰腺抗体（PAB）和抗酿酒酵母抗体（ASCA）。对临床特征数据进行分析。
IgG抗FcεRI是CD的有效标志物（<0.001），但IgE和IgG抗IgE不是（分别为=0.089、0.219）。抗IgE与抗FcεRI之间存在正相关（R=0.380，<0.001）。抗FcεRI阳性患者疾病活动度较高[比值比（OR）：1.478（1.2001.821），<0.001]，但在蒙特利尔分类中位于L4的可能性较小[OR：0.253（0.0770.837），=0.024]。现有指标PAB和ASCA特异性高（均>95%）但敏感性低（均<30%）。抗FcεRI与现有标志物联合使用显著提高了诊断效率[曲线下面积（AUC）：0.879（0.831~0.928）]。
建立并验证了一种检测抗FcεRI的ELISA法，这可能有助于促进对克罗恩病的研究。抗FcεRI阳性的CD患者与较高的疾病活动指数相关，提示其在CD诊断和管理中的潜在价值。
